Abbott Laboratories’ (ABT) Overweight Rating Reaffirmed at Barclays

Abbott Laboratories (NYSE:ABT)‘s stock had its “overweight” rating reaffirmed by analysts at Barclays in a research note issued on Monday, Stock Target Advisor reports. They presently have a $158.00 target price on the healthcare product maker’s stock. Barclays‘s price target would indicate a potential upside of 26.28% from the stock’s previous close.

A number of other research analysts have also issued reports on ABT. Raymond James reiterated a “buy” rating and set a $129.00 target price (up previously from $122.00) on shares of Abbott Laboratories in a research report on Monday, October 14th. Sanford C. Bernstein increased their price objective on shares of Abbott Laboratories from $133.00 to $138.00 and gave the company an “outperform” rating in a report on Thursday, October 17th. Jefferies Financial Group boosted their target price on shares of Abbott Laboratories from $120.00 to $125.00 and gave the stock a “hold” rating in a research note on Thursday, October 17th. UBS Group raised their price target on shares of Abbott Laboratories from $146.00 to $148.00 and gave the company a “buy” rating in a research note on Thursday. Finally, Morgan Stanley boosted their price objective on Abbott Laboratories from $107.00 to $117.00 and gave the stock an “equal weight” rating in a research note on Thursday, October 17th. Four investment analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $133.06.

Abbott Laboratories Stock Up 1.5 %

Abbott Laboratories stock opened at $125.12 on Monday. Abbott Laboratories has a 52 week low of $99.71 and a 52 week high of $125.67. The firm has a market cap of $217.01 billion, a price-to-earnings ratio of 16.36, a price-to-earnings-growth ratio of 2.51 and a beta of 0.73. The business’s 50-day moving average price is $115.26 and its 200 day moving average price is $113.46. The company has a quick ratio of 1.14, a current ratio of 1.60 and a debt-to-equity ratio of 0.32.

Abbott Laboratories (NYSE:ABT) last posted its earnings results on Wednesday, January 22nd. The healthcare product maker reported $1.34 earnings per share for the quarter, meeting the consensus estimate of $1.34. Abbott Laboratories had a net margin of 31.95% and a return on equity of 20.74%. The firm had revenue of $10.97 billion during the quarter, compared to analyst estimates of $11,029,400 billion. During the same period in the previous year, the firm earned $1.19 EPS. The business’s quarterly revenue was up 7.2% on a year-over-year basis. As a group, sell-side analysts anticipate that Abbott Laboratories will post 5.15 earnings per share for the current year.

Hedge Funds Weigh In On Abbott Laboratories

A number of institutional investors have recently bought and sold shares of the company. Future Financial Wealth Managment LLC purchased a new position in shares of Abbott Laboratories during the 3rd quarter worth $31,000. Peterson Financial Group Inc. acquired a new position in Abbott Laboratories in the third quarter valued at about $32,000. Valued Wealth Advisors LLC boosted its stake in Abbott Laboratories by 78.4% during the third quarter. Valued Wealth Advisors LLC now owns 289 shares of the healthcare product maker’s stock worth $33,000 after buying an additional 127 shares during the period. Highline Wealth Partners LLC acquired a new stake in shares of Abbott Laboratories during the third quarter valued at about $37,000. Finally, JDM Financial Group LLC raised its stake in shares of Abbott Laboratories by 51.3% in the 3rd quarter. JDM Financial Group LLC now owns 363 shares of the healthcare product maker’s stock valued at $41,000 after acquiring an additional 123 shares during the period. 75.18% of the stock is owned by hedge funds and other institutional investors.

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.